Guerbet: 2015 annual revenue
Excellent level of activity in 2015
€449.4 million in revenue: +10.0% at constant exchange rates
VILLEPINTE, France, Feb. 10, 2016 (GLOBE NEWSWIRE) -- Guerbet (FR0000032526 GBT), a global specialist in contrast agents and medical imaging solutions, is reporting €460.8 million in revenue for financial year 2015, representing a 12.7% increase on a like-for-like basis. At constant exchange rates, revenue grew by 10.0% to €449.4 million.
Consolidated Group revenue excluding integration of CMDS (IFRS)
Very good activity in the fourth quarter: €117.1 million
Strong sales growth in 2015: +12.7%
Strong performance of the four business segments
Driven by Dotarem, the MRI segment grew the most in absolute value with a 21.7% increase. With €204.8 million in revenue, this segment now represents the majority of the Group's product mix, accounting for 44.4% of sales.
The X-ray segment increased by 1.9% to €191.4 million. Sales benefited from a favourable volume effect from Xenetix®.
With steady sales for Lipiodol and Patent Blue V, the IRT segment continued to rise considerably at a rate of more than 40% over the financial year.
The Imaging Solutions and Services (ISS) segment saw 3.8% growth, with sales amounting to €17.9 million.
Integration of the "CMDS" activity starting from 1 December 2015
2016, a year of transition for the Group
With nearly 90 years' experience, Guerbet is a pioneer in the contrast agent field and the global specialist of the medical imaging market. It offers a comprehensive range of X-Ray, Magnetic Resonance Imaging (MRI) and Interventional Radiology and Theranostics (IRT) products, along with a range of injectors and related medical devices to improve the diagnosis and treatment of patients. The acquisition of Mallinckrod's "contrast media and delivery systems" (CMDS) activity has doubled its size with an expanded offering. In 2014, the combined pro forma sales of Guerbet and the CMDS activity represented approximately €800 million, with around 2,500 employees. Guerbet (GBT) is listed on NYSE Euronext Paris (Segment B - Mid Caps).
For more information about Guerbet, please visit www.guerbet.com
Press release http://hugin.info/159769/R/1985322/728063.pdf